2600 VIA FORTUNA, SUITE 360, AUSTIN, TX
Shareholder votes
Material disclosure
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
End of Material Contract, Costs of Shutting Down or Selling Parts of the Business, Changes in Board, Management or Compensation
Earnings Release
Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
Changes in Board, Management or Compensation
Q3
Notice of Late Filing for Quarterly Report
Q2
Q1
FY 2023
Effectiveness Notice
SEC Form 25 - Delisting Notification
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS
Post-Effective Amendment to Registration Statement
Correspondence